Fig. 6.

In vivo anti-tumor effect in a 4T1-bearing mice model after treatment with mEHGZ combined with anti-PD-L1 antibody. A) Schematic diagram of the therapeutic schedule. The mice were intratumorally injected with EPI, EZ, GHZ, EHGZ, mEHGZ, anti-PD-L1 antibody, and mEHGZ + anti-PD-L1 antibody at an EPI dose of 3 mg/kg or intraperitoneal administrated with anti PD-L1 antibody of 100 μg, saline was uses as a blank control (n = 5). B) Tumor growth curves of mice after different treatments. C) Tumor weights after different treatments on day 24. D) Changes in the mice body weights in each experimental group. E-F) TUNEL and KI67 staining of the tumor tissue after different treatments (scale bar = 50 μm). G) H&E staining of lung tissues at the end of the anti-tumor experiment (scale bar = 100 μm). Data are represented as means ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.